Tenofovir disoproxil fumarate is not associated with a lower risk of hepatocellular carcinoma compared to entecavir in patients with chronic hepatitis B

• 作者: Hye Won Lee Seung Up Kim
• 来源期刊: 肝癌研究（英文版）
• 年，卷（期）: 2022,（3）
• 所属期刊栏目: Perspective
• 页码范围: 52-56
• 页数: 5页
• 语种: 英文
• DOI: 10.20517/2394-5079.2021.114

摘要

A paper published several years ago suggested that tenofovir disoproxil fumarate (TDF) was superior to entecavir (ETV) for reducing the risk of hepatocellular carcinoma (HCC). Since then, many observational studies have been conducted comparing TDF and ETV. Many studies in Asia demonstrated similar HCC risks between ETV and TDF groups. Similarly, recent studies involving Caucasian and European did not observe any differences in HCC risk between these groups. In this article, we briefly review studies that compared the incidence rates of HCC between ETV and TDF and discuss potential reasons for the discrepant results.